Sitaxentan (brand name Thelin) is a medication used to treat pulmonary arterial hypertension (PAH). It is used in people with a certain gene mutation and is taken by mouth once a day. It works by blocking the endothelin receptor, which is a factor in the development and progression of PAH. Common side effects include headache, nausea, fatigue, and dizziness.
Sitaxentan was a medication used to treat pulmonary arterial hypertension (PAH), a condition that causes high blood pressure in the arteries that supply blood to the lungs. It was marketed under the trade name Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. However, in 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.
Sitaxentan is an endothelin receptor antagonist, a type of medication that works by blocking the action of a substance called endothelin. Endothelin is a molecule that causes blood vessels to narrow. By blocking the action of endothelin, sitaxentan helped to relax blood vessels and improve blood flow to the lungs.